icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections (CROI)
February 22-25, 2016, Boston MA
Back grey_arrow_rt.gif
 
 
 
CROI 2016 - Themed Discussion: Rants About HCV RAVS
 
 
  I have included links to 2 talks -
 
(1)Genotypic and Phenotypic Characterization of Clinical HCV NS5A Drug Resistance Wei Huang, Monogram Biosciences, South San Francisco, CA, United States
 
(2)Retreatment with Harvoni of 34 Patients Treated Only for Short-Duration 4-6 Weeks with Harvoni in SYNERGY Trial, Eleanor Wilson, NIAID SYNERGY Trial
 
WEBCAST for Dr Huang's
talk:http://www.croiwebcasts.org/console/player/29510?mediaType=audio&
 
She reported on an analysis of prevalence & drug susceptibility to NS5A resistance mutations (RAVs) on 973 samples submitted to Monogram for routine NS5A resistance testing.

CROI1

Retreatment with Harvoni of 34 Patients Treated Only for Short-Duration 4-6 Weeks with Harvoni in SYNERGY Trial
 
Many of these patients had high level NS5A resistance but SVR Rates in the retreatment study were 85-90%
 
WEBCAST for Dr Wilson's
talk:http://www.croiwebcasts.org/console/player/29514?mediaType=audio&

CROI2

CROI3

CROI4